Skip to main content
. 2022 Jul 1;113(8):2814–2827. doi: 10.1111/cas.15462

FIGURE 2.

FIGURE 2

Kaplan–Meier estimates of progression‐free survival in Japanese patients with gastric cancer treated with (A) first‐line pembrolizumab with S‐1 + oxaliplatin (cohort 1) or (B) first‐line pembrolizumab with S‐1 + cisplatin (cohort 2), assessed by central review